A single dose of the long-acting antibody nirsevimab developed to prevent respiratory syncytial virus infections in infants ...

Discover a study that highlights the importance of identifying high-risk children through biomarkers and better understanding ...

A single dose of the long-acting antibody nirsevimab developed to prevent respiratory syncytial virus infections (The drug ...

A single dose of the long-acting antibody nirsevimab to infants can halve hospitalizations for bronchiolitis.

Respiratory Syncytial Virus (RSV) poses a significant threat to Indian infants, particularly during post-monsoon and winter, ...

RSV leads to over 100,000 infant deaths annually, but WHO’s latest guidance recommends maternal vaccines and monoclonal ...

The first bacteria our bodies meet – in the hours after we're born – could protect us from dangerous infections, UK ...

A substantial burden of hospitalizations for PIV-associated ARI was observed among pediatric patients in the United States.

RSV causes about 100,000 deaths and more than 3.6 million hospitalisations in children under the age of 5 worldwide ...

Adults with RSV-associated acute respiratory infection face a 2.7-fold higher risk for death within one year, according to a ...

The new three-illness dashboard includes a history of outbreaks for any or all of the three respiratory illnesses. It ...

"Respiratory viral infections (RVIs) are associated with elevated cardiovascular risk; however, less is known about cardiac ...